NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Genascence Corporation

Genascence Corporation

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://genascence.com/

Last Round

Grant

Feb 23, 2023

Total Funding Raised

$22.1M

Company Overview

Genascence Corporation is a biotechnology company developing gene therapies for prevalent musculoskeletal and joint diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyosteoarthritis treatmentAAV vectoradeno-associated virusmusculoskeletal diseaseinterleukin-1 receptor antagonistIL-1Rabiotech startupclinical-stage biotechintra-articular injectiondisease-modifying therapydrug developmentbiopharmaknee osteoarthritisregenerative medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genascence Corporation Comparables

Compare Genascence Corporation with similar companies based on industry and business-model similarity.

Genascence Corporation comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ICM Co., Ltd.
83%
Xalud Therapeutics
83%
Kolon TissueGene, Inc.
82%

Genascence Corporation Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 23, 2023
Series AMay 10, 2022

Key People

Founding team and executive leadership

Annahita Keravala

Founder Chief Scientific Officer

Founding Team

Thomas W. Chalberg

Founder CEO

Founding Team

Genascence Corporation Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 23, 2023

    $12M grant received from California Institute for Regenerative Medicine.

Genascence Corporation Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genascence Corporation Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genascence Corporation's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range4
Year Founded2017
Last FundingFeb 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.